EUVIMEDEUVIMED entdecken
EditorialKommentar

Commentary: Who should be using ex vivo lung perfusion?

Isaac S Alderete, Matthew G Hartwig

The Journal of Thoracic and Cardiovascular Surgery · 2024

DOI: 10.1016/j.jtcvs.2023.04.047 ↗

Kurz gefasst

Editorial in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2024. Verfasst von Isaac S Alderete und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Duke University, Durham, NC. Hauptthemen laut MEDLINE: Lung, Lung Transplantation. Die Arbeit nennt 9 Literaturangaben. Gefördert von: NCATS NIH HHS, National Center for Advancing Translational Sciences, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The use of ex vivo lung perfusion (EVLP) has revolutionized lung transplantation (LTx) by allowing greater organ preservation time, improved operating room logistics, and use of marginal grafts that may not otherwise be transplanted. 1-3 Although the use of EVLP has become more widespread within the past decade, not all transplant centers utilize the technology, with some being slower than others to implement it. Some barriers relate to the infrastructure and expertise that are required to develop an EVLP program. The degree to which these are present at a transplant center may lead to differences in outcomes when using the technology. 4 Chen and colleagues 5 evaluated the influence that transplant center experience with EVLP may have on LTx outcomes. They assessed the clinical outcomes of 41 transplant centers in the United States that utilize the technology. After stratifying the centers into high and low users of EVLP, the authors found that lung recipients at low-volume centers ( < 15 EVLP transplants over 4 years) had significantly worse 1-year adjusted rates of survival after transplant. They demonstrated that the low-volume center recipients had significantly worse 1-year survival when receiving EVLP donor lungs compared with when the same centers used non-EVLP lungs. On the contrary, higher-volume EVLP centers had comparable outcomes between their non-EVLP and EVLP LTx procedures. The results of this study are consistent with prior work demonstrating that transplant center volume, and thus experience, is directly associated with LTx outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LungLung TransplantationHumansExtracorporeal CirculationPerfusionOrgan Preservation

Autor:innen und Institutionen

  • School of Medicine, Duke University, Durham, NC.
  • Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University, Medical Center, Durham, NC. Electronic address: matthew.hartwig@duke.edu.

Förderung

  • NCATS NIH HHS
  • National Center for Advancing Translational Sciences
  • National Institutes of Health

Zitieren

APA

Alderete, I. S., & Hartwig, M. G. (2024). Commentary: Who should be using ex vivo lung perfusion?. The Journal of Thoracic and Cardiovascular Surgery. https://doi.org/10.1016/j.jtcvs.2023.04.047

Vancouver

Alderete IS, Hartwig MG. Commentary: Who should be using ex vivo lung perfusion?. The Journal of Thoracic and Cardiovascular Surgery. 2024. doi:10.1016/j.jtcvs.2023.04.047

BibTeX
@article{Alderete2024,
  author = {Alderete, Isaac S and Hartwig, Matthew G},
  title = {Commentary: Who should be using ex vivo lung perfusion?},
  journal = {The Journal of Thoracic and Cardiovascular Surgery},
  year = {2024},
  doi = {10.1016/j.jtcvs.2023.04.047}
}
Kostenlos starten →